MedTrace Logo

Botulinum Toxin and Mesotherapy on Enhancement of Facial Scarring

NCT06562023 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2024-08-20

No results posted yet for this study

Summary

Most of the body's tissues can undergo wound repair following a disruption of tissue integrity. Upon healing, these wounds result in scar formation. The scars widen when the overlying musculature pulls apart suture lines. Botulinum Toxin A (BTA) is known to prevent fibroblast proliferation and it also induces temporary muscle paralysis. Also, mesotherapy is the non-invasive transdermal injection which can aid the skin to increase collagen and elastin production. Thus, both techniques are eligible for enhancement of facial scars.

Conditions

  • Facial Scars

Interventions

OTHER

Botulinum Toxin Type A

Patients will receive BTA injection within a period of 5 days after primary closure.

OTHER

Mesotherapy

Patients will receive mesotherapy growth factor serum with a derma pen within a period of 5 days after primary closure.

Sponsors & Collaborators

  • Hams Hamed Abdelrahman

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-19
Primary Completion
2024-07-20
Completion
2024-07-20

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06562023 on ClinicalTrials.gov